Literature DB >> 20102883

Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).

Mariusz Kruk1, Christopher E Buller, James Enlou Tcheng, Vladimir Dzavík, Venugopal Menon, G B John Mancini, Sandra A Forman, Peter Kurray, Benita Busz-Papiez, Gervasio A Lamas, Judith S Hochman.   

Abstract

In the Occluded Artery Trial (OAT), percutaneous coronary intervention (PCI) of an infarct-related artery on days 3 to 28 after acute myocardial infarction was of no benefit compared to medical therapy alone. The present analysis was conducted to determine whether PCI might provide benefit to the subgroup of higher risk patients with a depressed ejection fraction (EF). Of 2,185 analyzed patients (age 58.6 +/- 11.0 years) with infarct-related artery occlusion on days 3 to 28 after acute myocardial infarction in the Occluded Artery Trial, 1,094 were assigned to PCI and 1,091 to medical therapy. The primary end point was a composite of death, reinfarction, and New York Heart Association class IV heart failure. The outcomes were analyzed by EF (first tertile, EF < or =44%, vs second and third tertiles combined, EF >44%). Interaction of the treatment effect with EF on the study outcomes were examined using the Cox survival model. The 5-year rates of the primary end point (death, reinfarction, or New York Heart Association class IV heart failure) were not different in either subgroup (PCI vs medical therapy, hazard ratio 1.25, 99% confidence interval 0.83 to 1.88, for EF < or =44%; hazard ratio 0.98, 99% confidence interval 0.64 to 1.50, for EF >44%). However, in patients with an EF >44%, PCI reduced the rate of subsequent revascularization (p = 0.004, interaction p = 0.05). In conclusion, optimal medical therapy remains the overall treatment of choice for stable patients with a persistent total occlusion of the infarct-related artery after acute myocardial infarction, irrespective of the baseline EF. In patients with normal or moderately impaired left ventricular contractility, PCI reduced the need for subsequent revascularization but did not otherwise improve outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20102883      PMCID: PMC2825873          DOI: 10.1016/j.amjcard.2009.08.644

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

Authors:  H J Dargie
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

2.  Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study).

Authors:  Zaheer R Yousef; Simon R Redwood; Clifford A Bucknall; Alfred N Sulke; Michael S Marber
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

3.  Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.

Authors:  I Moussa; C Di Mario; B Reimers; T Akiyama; J Tobis; A Colombo
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

4.  The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.

Authors:  James E Udelson; Camille A Pearte; Carey D Kimmelstiel; Mariusz Kruk; Joseph A Kufera; Sandra A Forman; Anna Teresinska; Bartosz Bychowiec; Jose Antonio Marin-Neto; Thomas Höchtl; Eric A Cohen; Paulo Caramori; Benita Busz-Papiez; Christopher Adlbrecht; Zygmunt P Sadowski; Witold Ruzyllo; Debra J Kinan; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2011-03       Impact factor: 4.749

5.  Surgical survival benefits for coronary disease patients with left ventricular dysfunction.

Authors:  E P Bounous; D B Mark; B G Pollock; M A Hlatky; F E Harrell; K L Lee; J S Rankin; A S Wechsler; D B Pryor; R M Califf
Journal:  Circulation       Date:  1988-09       Impact factor: 29.690

6.  Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study).

Authors:  V Dzavik; D S Beanlands; R F Davies; D Leddy; J F Marquis; K K Teo; T D Ruddy; J R Burton; D P Humen
Journal:  Am J Cardiol       Date:  1994-05-01       Impact factor: 2.778

7.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; P W Brandt; R M Whitlock; C J Wild
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

8.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

9.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.

Authors:  J D Rutherford; M A Pfeffer; L A Moyé; B R Davis; G C Flaker; P R Kowey; G A Lamas; H S Miller; M Packer; J L Rouleau
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

10.  Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data.

Authors: 
Journal:  Circulation       Date:  1983-11       Impact factor: 29.690

View more
  2 in total

1.  Introduction and Vision.

Authors:  Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2020-02       Impact factor: 3.727

2.  Heart failure in post-MI patients with persistent IRA occlusion: prevalence, risk factors, and the long-term effect of PCI in the Occluded Artery Trial (OAT).

Authors:  Rahul R Jhaveri; Harmony R Reynolds; Stuart D Katz; Raban Jeger; Elzbieta Zinka; Sandra A Forman; Gervasio A Lamas; Judith S Hochman
Journal:  J Card Fail       Date:  2012-11       Impact factor: 5.712

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.